Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures

被引:162
作者
Donnelly, Eve [1 ]
Meredith, Dennis S.
Nguyen, Joseph T.
Gladnick, Brian P.
Rebolledo, Brian J.
Shaffer, Andre D.
Lorich, Dean G.
Lane, Joseph M.
Boskey, Adele L. [1 ,2 ]
机构
[1] Hosp Special Surg, Mineralized Tissues Lab, New York, NY 10021 USA
[2] Cornell Univ, Weill Med Coll, Grad Program Physiol Biophys & Syst Biol, New York, NY 10021 USA
关键词
FOURIER TRANSFORM INFRARED IMAGING; CORTICAL BONE; MATERIAL PROPERTIES; HIP FRACTURE; ATYPICAL SUBTROCHANTERIC FRACTURE; NONENZYMATIC GLYCATION; MECHANICAL-PROPERTIES; INTERVENTION TRIAL; 1-YEAR TREATMENT; CANCELLOUS BONE; MINERAL-CONTENT; ALENDRONATE; OSTEOPOROSIS; REDUCTION; RISK;
D O I
10.1002/jbmr.560
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Reduction of bone turnover with bisphosphonate treatment alters bone mineral and matrix properties. Our objective was to investigate the effect of bisphosphonate treatment on bone tissue properties near fragility fracture sites in the proximal femur in postmenopausal women with osteoporosis. The mineral and collagen properties of corticocancellous biopsies from the proximal femur were compared in bisphosphonate-naive (-BIS, n?=?20) and bisphosphonate-treated (+BIS, n?=?20, duration 7?+/-?5 years) patients with intertrochanteric (IT) and subtrochanteric (ST) fractures using Fourier transform infrared imaging (FTIRI). The mean values of the FTIRI parameter distributions were similar across groups, but the widths of the parameter distributions tended to be reduced in the +BIS group relative to the -BIS group. Specifically, the widths of the cortical collagen maturity and crystallinity were reduced in the +BIS group relative to those of the -BIS group by 28% (+BIS 0.45?+/-?0.18 versus -BIS 0.63?+/-?0.28, p?=?0.03) and 17% (+BIS 0.087?+/-?0.012 versus -BIS 0.104?+/-?0.036, p?=?0.05), respectively. When the tissue properties were examined as a function of fracture morphology within the +BIS group, the FTIR parameters were generally similar regardless of fracture morphology. However, the cortical mineral:matrix ratio was 8% greater in tissue from patients with atypical ST fractures (n?=?6) than that of patients with typical (IT or spiral ST) fractures (n?=?14) (Atypical 5.6?+/-?0.3 versus Typical 5.2?+/-?0.5, p?=?0.03). Thus, although the mean values of the FTIR properties were similar in both groups, the tissue in bisphosphonate-treated patients had a more uniform composition than that of bisphosphonate-naive patients. The observed reductions in mineral and matrix heterogeneity may diminish tissue-level toughening mechanisms. (c) 2012 American Society for Bone and Mineral Research
引用
收藏
页码:672 / 678
页数:7
相关论文
共 34 条
[1]   Variations in trabecular bone composition with anatomical site and age: potential implications for bone quality assessment [J].
Aerssens, J ;
Boonen, S ;
Joly, J ;
Dequeker, J .
JOURNAL OF ENDOCRINOLOGY, 1997, 155 (03) :411-421
[2]   Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra [J].
Allen, M. R. ;
Gineyts, E. ;
Leeming, D. J. ;
Burr, D. B. ;
Delmas, P. D. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (03) :329-337
[3]   Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment [J].
Allen, Matthew R. ;
Burr, David B. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (11) :1759-1765
[4]   Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate [J].
Allen, Matthew R. ;
Iwata, Ken ;
Phipps, Roger ;
Burr, David B. .
BONE, 2006, 39 (04) :872-879
[5]   Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: What we think we know and what we know that we don't know [J].
Allen, Matthew R. ;
Burr, David B. .
BONE, 2011, 49 (01) :56-65
[6]   Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].
Black, Dennis M. ;
Delmas, Pierre D. ;
Eastell, Richard ;
Reid, Ian R. ;
Boonen, Steven ;
Cauley, Jane A. ;
Cosman, Felicia ;
Lakatos, Peter ;
Leung, Ping Chung ;
Man, Zulema ;
Mautalen, Carlos ;
Mesenbrink, Peter ;
Hu, Huilin ;
Caminis, John ;
Tong, Karen ;
Rosario-Jansen, Theresa ;
Krasnow, Joel ;
Hue, Trisha F. ;
Sellmeyer, Deborah ;
Eriksen, Erik Fink ;
Cummings, Steven R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822
[7]   Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur [J].
Black, Dennis M. ;
Kelly, Michael P. ;
Genant, Harry K. ;
Palermo, Lisa ;
Eastell, Richard ;
Bucci-Rechtweg, Christina ;
Cauley, Jane ;
Leung, Ping Chung ;
Boonen, Steven ;
Santora, Arthur ;
de Papp, Anne ;
Bauer, Douglas C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (19) :1761-1771
[8]   Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].
Black, Dennis M. ;
Schwartz, Ann V. ;
Ensrud, Kristine E. ;
Cauley, Jane A. ;
Levis, Silvina ;
Quandt, Sara A. ;
Satterfield, Suzanne ;
Wallace, Robert B. ;
Bauer, Douglas C. ;
Palermo, Lisa ;
Wehren, Lois E. ;
Lombardi, Antonio ;
Santora, Arthur C. ;
Cummings, Steven R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938
[9]   Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial [J].
Black, DM ;
Thompson, DE ;
Bauer, DC ;
Ensrud, K ;
Musliner, T ;
Hochberg, MC ;
Nevitt, MC ;
Suryawanshi, S ;
Cummings, SR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11) :4118-4124
[10]   Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].
Bone, HG ;
Hosking, D ;
Devogelaer, J ;
Tucci, JR ;
Emkey, RD ;
Tonino, RP ;
Rodriguez-Portales, JA ;
Downs, RW ;
Gupta, J ;
Santora, AC ;
Liberman, UA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199